TARA Protara Therapeutics, Inc.
Price Chart
Executive Summary
Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effective on May 22, 2026. This enables the company to conduct primary and/or secondary offerings of securities at any time, creating potential dilution overhang for common stock shareholders. The effectiveness comes as the company's $277M market cap biotech carries strong analyst bullish consensus (93% buy) but with negative historical alpha at T+20.
Actionable Insight
Traders should watch for a prospectus supplement announcing a priced offering, which typically follows effectiveness within days to weeks for clinical-stage biotechs. Any announced offering size below ~$50M may be digestible; a larger raise could pressure the stock given the weak T+20 historical performance on recent filings. Monitor insider buying/selling patterns for signals on whether management views the current valuation as attractive ahead of potential dilution.
Key Facts
- Form S-3 shelf registration became effective May 22, 2026.
- Registration covers issuance of common stock, preferred stock, warrants, debt securities, and/or units.
- No specific pricing, amount, or intended use of proceeds was disclosed in the effectiveness notice.
- Company is a clinical-stage biotech with $277M market cap and 93% analyst buy rating.
- Historical TARA filings have shown negative mean alpha at T+20 (-2.78%) in the filing_report segment.
Financial Impact
Undisclosed — no offering size or terms were provided in the effectiveness notice. Shelf registration is effective immediately, so the company can conduct offerings at any time.
Risk Factors
- Immediate risk: company may announce a dilutive offering at any time now that the shelf is effective.
- Clinical-stage biotech with no approved products — pipeline failure could compound dilution risk.
- Negative T+20 alpha on prior TARA filings suggests bearish momentum over medium-term windows.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001748 |
| Document: 9999999995-26-001748-index.html | 9999999995-26-001748 |
| Document: 9999999995-26-001748.txt | 9999999995-26-001748 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
EFFECT
| $4.80 $4.34 | ▲ +9.58% | ▲ +10.80% | $3.90 (+18.75%) |
|
May 16, 2026
27d ago
|
ANALYST-UPGRADE
| $6.20 $5.60 | ▼ −9.68% | ▼ −8.34% | $3.90 (−37.10%) |
|
May 15, 2026
29d ago
|
Press Release
| $5.10 $4.92 | ▼ −3.53% | ▼ −4.49% | $3.90 (−23.53%) |
|
May 13, 2026
4w ago
|
8-K
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
May 13, 2026
4w ago
|
Press Release
| $5.20 $4.34 | ▼ −16.54% | ▼ −15.38% | $3.90 (−25.00%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $5.17 $5.66 | ▲ +9.48% | ▲ +6.37% | $3.90 (−24.56%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $5.13 $5.26 | ▲ +2.53% | ▲ +1.55% | $3.90 (−23.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access